As of May 2026, Crown Reserve Acquisition Corp. I has entered into a Business Combination Agreement with Carvix, Inc., advancing its transition from a blank check company to an operating entity subject to customary closing conditions.

• On March 30, 2026, Crown Reserve Acquisition Corp. I entered into a Business Combination Agreement with Carvix, Inc., subject to stockholder approval, SEC registration effectiveness, Nasdaq listing approval, and other customary conditions [S2].
• Failure to complete the Business Combination by the outside date of September 30, 2026, or any mutually agreed extension, may result in termination of the agreement and liquidation of the company [S2].
• The company reported a net loss of $263,493 for the quarter ended March 31, 2026, and had a current ratio of 0.08, indicating limited liquidity outside the Trust Account [S2].

The company’s management team has significant experience in identifying and executing mergers and acquisitions across multiple sectors, supported by a broad network of relationships that may provide access to attractive proprietary deal flow. The substantial capital held in the Trust Account offers financial flexibility to structure business combinations using cash, equity, or debt. The company’s generalist acquisition strategy allows it to pursue opportunities across industries and geographies, potentially enabling it to capitalize on diverse market conditions. The planned Business Combination with Carvix, Inc. represents a material step toward operational activity and value creation for shareholders.

The company currently has no operating history, revenues, or full-time employees, which limits visibility into its ability to execute a successful business combination. The limited liquidity outside the Trust Account and net loss reported for the quarter highlight financial constraints prior to a business combination. The Business Combination Agreement with Carvix, Inc. is subject to multiple closing conditions, and failure to complete the transaction by the outside date may result in liquidation and redemption of public shares, potentially leading to loss of investment. The broad acquisition mandate without industry or geographic focus may expose the company to risks related to unfamiliar sectors or markets. Additionally, the company’s status as an emerging growth and smaller reporting company entails reduced disclosure obligations, which may affect transparency.

As a SPAC, Crown Reserve Acquisition Corp. I’s competitive strengths derive from its experienced management team with broad sector expertise and capital markets experience, a substantial Trust Account providing capital for acquisitions, and a broad, flexible acquisition mandate. The management team’s extensive network across private equity, investment banking, and corporate sectors provides access to proprietary deal flow and investment opportunities. The company’s ability to offer target businesses price certainty, speed of execution, and access to public capital markets through a business combination differentiates it from traditional IPOs or private sales. However, the company’s moat is contingent on successfully identifying and completing a suitable business combination within the prescribed timeframe.

• Completion of Business Combination: The company must complete a business combination within the prescribed timeframe (12 months from IPO closing, extendable to 15 months) or face liquidation and redemption of public shares.
• Business Combination Agreement Conditions: The Business Combination with Carvix, Inc. is subject to customary closing conditions including stockholder approval, SEC registration effectiveness, Nasdaq listing approval, and minimum cash requirements, any of which may not be satisfied.
• Limited Operating History and Financial Position: The company has no operating history, no revenues, and reported a net loss for the quarter ended March 31, 2026. Liquidity outside the Trust Account is limited, with a current ratio of 0.08.
• Management and Execution Risk: The company relies on its management team’s ability to identify and complete a suitable business combination. Management’s time may be divided among other activities, and there is no guarantee of success.
• Broad Acquisition Mandate: The company’s lack of industry or geographic focus may expose it to risks related to unfamiliar sectors or markets, potentially affecting the success of the business combination.
• Regulatory and Market Risks: The company is subject to SEC reporting requirements and Nasdaq listing rules. Changes in regulatory environment or market conditions may impact the business combination process and post-combination operations.

• Crown Reserve Acquisition Corp. I is a Cayman Islands exempted blank check company formed on April 29, 2025, to complete a business combination.
• The company completed an IPO on November 10, 2025, raising $172.5 million placed in a Trust Account invested in U.S. government securities.
• 375,000 Private Placement Units were sold simultaneously, raising an additional $3 million.
• The company has no operating history, no revenues, and no full-time employees; management devotes time as needed until a business combination.
• The company has a 12-month period from IPO closing (Nov 10, 2026) to complete a business combination, extendable to 15 months upon agreement execution.
• Management has extensive experience across multiple sectors and capital markets transactions.
• The company pursues a generalist acquisition strategy without industry or geographic limitation.
• A Business Combination Agreement with Carvix, Inc. was entered on March 30, 2026, subject to customary closing conditions.
• Failure to complete the business combination by the outside date may lead to liquidation and redemption of public shares.
• As of March 31, 2026, current assets were $273,570 and current liabilities $3,434,455, with a current ratio of 0.08, indicating limited liquidity outside the Trust Account.
• The company reported a net loss of $263,493 for Q1 2026.
• Units, shares, warrants, and rights began separate trading on Nasdaq in December 2025.
• Trust Account funds are restricted until completion of the business combination, except for tax payments and redemptions.
• The company is an emerging growth and smaller reporting company with reduced disclosure obligations.
• Management intends active involvement in target businesses post-combination.
• Sponsor holds 4,312,500 Class B shares with transfer restrictions until after the business combination.
• Public warrants exercisable at $11.50 per share become exercisable after the business combination or 12 months post-IPO, expiring five years later.
• Rights entitle holders to 0.20 Class A shares upon business combination; rights expire worthless if no combination occurs.